iX Biopharma

iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil - THE EDGE SINGAPORE

Healthcare

iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil

iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
iX Biopharma narrows FY2021 loss on higher sales  - THE EDGE SINGAPORE

Results

iX Biopharma narrows FY2021 loss on higher sales

The demand in China grew thanks to careful spent on marketing which helped drive awareness and interest.
iX Biopharma to export medicinal cannabis wafers in New Zealand - THE EDGE SINGAPORE

Company in the news

iX Biopharma to export medicinal cannabis wafers in New Zealand

The agreement will allow iX Biopharma to access New Zealand’s pharmaceutical market.
iX Biopharma exploring spin-off and listing of pharmaceutical business on HKEX - THE EDGE SINGAPORE

Healthcare

iX Biopharma exploring spin-off and listing of pharmaceutical business on HKEX

iX Biopharma intends to spin-off its pharmaceutical business by way of a listing on the main board of the HKEX.
iX Biopharma gets green light to export medicinal cannabis wafers - THE EDGE SINGAPORE

Company in the news

iX Biopharma gets green light to export medicinal cannabis wafers

iX Biopharma says it will commence supply of the wafers to Brazil as part of its overseas market expansion.
Broker's Digest: Venture Corp, Grand Venture Technology, Sasseur REIT, iX Biopharma - THE EDGE SINGAPORE

Broker's Calls

Broker's Digest: Venture Corp, Grand Venture Technology, Sasseur REIT, iX Biopharma, SGX

See the analysts' recommendations and target prices here.
iX Biopharma ketamine wafers to be evaluated for cancer pain treatment in Australian study - THE EDGE SINGAPORE

Healthcare

iX Biopharma ketamine wafers to be evaluated for cancer pain treatment in Australian study

The company says the study unlocks Wafermine’s potential to address the global cancer pain market, estimated at US$5.5 bil.
Continue to 'buy' iX Biopharma as expanded product use and capacity should provide stock catalysts: PhillipCapital - THE EDGE SINGAPORE

Broker's Calls

Continue to 'buy' iX Biopharma as expanded product use and capacity should provide stock catalysts: PhillipCapital

PhillipCapital has maintained its target price of 44.5 cents for iX Biopharma.
iX Biopharma to expand wafer production capacity at Australian facility - THE EDGE SINGAPORE

Company in the news

iX Biopharma to expand wafer production capacity at Australian facility

New freeze-dry equipment will boost the production of its WaferiX wafers up to six times its current capacity.
×